The potential value of negative studies [4]

Journal of the American Medical Directors Association

Volumn 6, Issue 6, 2005, Pages 426-

  Cheng, Huai Yong ^a  

^a Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL STUDY; DATA ANALYSIS; LETTER; NURSING HOME; OCCUPATIONAL DISEASE; SAMPLE SIZE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

EID: 28744457546     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2005.09.007     Document Type: Letter

References (8)

1. H.T. Hatoum, S.J. Lin, S. Arcona The use of the occupational disruptiveness scale of the Neuropsychiatric Inventory-Nursing Home Version to measure the impact of Rivastigmine on the disruptive behavior of nursing home residents with Alzheimer's disease J Am Med Dir Assoc 6 2005 238 245
2. J. Mittelberger The impact of acetylcholinergic medications on Alzheimer's disease-related behavioral disorders in nursing home patients What is the real impact? J Am Med Dir Assoc 6 2005 282 283
3. K. Dickersin, D. Rennie Registering clinical trials JAMA 290 2003 516 523
4. D. Moher, C.S. Dulberg, G.A. Wells Statistical power, sample size, and their reporting in randomized controlled trials JAMA 272 1994 122 124
5. M. Bhandari, J.W. Busse, D. Jackowski Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials CMAJ 170 2004 477 480
6. S.J. Pocock, M.D. Hughes, R.J. Lee Statistical problems in the reporting of clinical trials - a survey of three medical journals N Engl J Med 317 1987 426 432
7. S.N. Goodman Toward evidence-based medical statistics. 1: The P value fallacy Ann Intern Med 130 1999 995 1004
8. J.M. Last A Dictionary of Epidemiology 4th ed. 2001 Oxford University Press, Inc New York, NY 168